DK2279200T3 - Biological active peptides - Google Patents

Biological active peptides Download PDF

Info

Publication number
DK2279200T3
DK2279200T3 DK09743243.9T DK09743243T DK2279200T3 DK 2279200 T3 DK2279200 T3 DK 2279200T3 DK 09743243 T DK09743243 T DK 09743243T DK 2279200 T3 DK2279200 T3 DK 2279200T3
Authority
DK
Denmark
Prior art keywords
peptide
val trp
prt
artificial sequence
seq
Prior art date
Application number
DK09743243.9T
Other languages
Danish (da)
English (en)
Inventor
Friedrich Scheiflinger
Michael Dockal
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Application granted granted Critical
Publication of DK2279200T3 publication Critical patent/DK2279200T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK09743243.9T 2008-04-17 2009-04-16 Biological active peptides DK2279200T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US932608P 2008-04-17 2008-04-17
US11305508P 2008-11-10 2008-11-10
PCT/US2009/040857 WO2009137256A1 (en) 2008-04-17 2009-04-16 Biologically active peptides

Publications (1)

Publication Number Publication Date
DK2279200T3 true DK2279200T3 (en) 2016-08-22

Family

ID=40887122

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09743243.9T DK2279200T3 (en) 2008-04-17 2009-04-16 Biological active peptides
DK16172509.8T DK3115370T3 (da) 2008-04-17 2009-04-16 Biologisk aktive peptider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16172509.8T DK3115370T3 (da) 2008-04-17 2009-04-16 Biologisk aktive peptider

Country Status (19)

Country Link
US (6) US8563688B2 (https=)
EP (2) EP3115370B1 (https=)
JP (3) JP6038452B2 (https=)
KR (2) KR101606248B1 (https=)
CN (2) CN105524163A (https=)
AR (1) AR071478A1 (https=)
AU (1) AU2009244635B2 (https=)
BR (1) BRPI0911203A2 (https=)
CA (1) CA2721694C (https=)
DK (2) DK2279200T3 (https=)
ES (2) ES2739676T3 (https=)
HK (1) HK1223946A1 (https=)
MX (1) MX2010011397A (https=)
NZ (1) NZ588200A (https=)
PL (1) PL2279200T3 (https=)
PT (1) PT2279200T (https=)
SG (2) SG10201809286XA (https=)
TW (2) TWI573806B (https=)
WO (1) WO2009137256A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI573806B (zh) * 2008-04-17 2017-03-11 巴克斯歐塔公司 生物活性胜肽
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2012012444A2 (en) 2010-07-19 2012-01-26 Dolby Laboratories Licensing Corporation Enhancement methods for sampled and multiplexed image and video data
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第viii因子組成物、ならびに組成物の作製方法および用途
HUE053223T2 (hu) * 2013-06-11 2021-06-28 Cj Cheiljedang Corp L-izoleucint termelõ mikroorganizmus és eljárás L-izoleucin elõállítására annak alkalmazásával
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子viii-xten融合物及其用途
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US20160039876A1 (en) 2014-03-28 2016-02-11 Claresa Levetan Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
JP6484468B2 (ja) * 2014-06-03 2019-03-13 AvanStrate株式会社 ガラス板製造方法およびガラス板製造装置
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
CA3038292A1 (en) 2016-09-28 2018-04-05 Cohbar, Inc. Therapeutic mots-c related peptides
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
NZ262679A (en) 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6005166A (en) * 1994-12-30 1999-12-21 Seminis Vegetable Seeds, Inc. Papaya ringspot virus replicase gene
US5532153A (en) * 1995-03-23 1996-07-02 New England Biolabs, Inc. Method for cloning and producing the SacI restriction endonuclease
US7279548B2 (en) * 1996-04-03 2007-10-09 Cytogen Corporation Identification and isolation of novel polypeptides having WW domains and methods of using same
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US6624289B1 (en) * 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US7109170B2 (en) * 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
IL147269A0 (en) * 1999-07-02 2002-08-14 Genentech Inc FVIIa ANTAGONISTS
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
AU2065801A (en) * 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
WO2001058479A1 (en) * 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2002092623A1 (en) * 2001-05-11 2002-11-21 Research Development Foundation INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
FR2830865B1 (fr) * 2001-10-17 2004-10-22 Centre Nat Rech Scient Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
US20060204503A1 (en) * 2005-01-31 2006-09-14 Biogen Idec Ma Inc. Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors
US20090215025A1 (en) * 2005-12-07 2009-08-27 Technische Universitat Munchen Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
KR20080087148A (ko) 2006-01-04 2008-09-30 두-쿱 테크놀로지스 리미티드 저온보호 조성물 및 그 이용방법
TWI573806B (zh) * 2008-04-17 2017-03-11 巴克斯歐塔公司 生物活性胜肽

Also Published As

Publication number Publication date
TW201443085A (zh) 2014-11-16
CA2721694A1 (en) 2009-11-12
AU2009244635B2 (en) 2012-04-19
EP3115370A1 (en) 2017-01-11
US8563688B2 (en) 2013-10-22
US20160060295A1 (en) 2016-03-03
JP2011518179A (ja) 2011-06-23
EP2279200B1 (en) 2016-07-13
AU2009244635A1 (en) 2009-11-12
SG10201809286XA (en) 2018-11-29
TW200944226A (en) 2009-11-01
ES2739676T3 (es) 2020-02-03
US10287319B2 (en) 2019-05-14
KR101434712B1 (ko) 2014-10-01
PL2279200T3 (pl) 2017-08-31
US20190225648A1 (en) 2019-07-25
TWI573806B (zh) 2017-03-11
KR101606248B1 (ko) 2016-03-24
CA2721694C (en) 2018-11-06
EP3115370B1 (en) 2019-06-26
EP2279200A1 (en) 2011-02-02
DK3115370T3 (da) 2019-07-29
HK1154255A1 (zh) 2012-04-13
HK1223946A1 (zh) 2017-08-11
SG10201608071YA (en) 2016-11-29
US9206234B2 (en) 2015-12-08
US20170174724A1 (en) 2017-06-22
US9598464B2 (en) 2017-03-21
CN102007140B (zh) 2016-02-24
CN105524163A (zh) 2016-04-27
JP5977223B2 (ja) 2016-08-24
NZ588200A (en) 2012-11-30
AR071478A1 (es) 2010-06-23
BRPI0911203A2 (pt) 2016-07-05
JP2014074052A (ja) 2014-04-24
JP6038452B2 (ja) 2016-12-07
US8822638B2 (en) 2014-09-02
PT2279200T (pt) 2016-10-12
US20120077749A1 (en) 2012-03-29
ES2594706T3 (es) 2016-12-22
KR20110005873A (ko) 2011-01-19
KR20130112959A (ko) 2013-10-14
TWI541020B (zh) 2016-07-11
JP2017019797A (ja) 2017-01-26
WO2009137256A1 (en) 2009-11-12
MX2010011397A (es) 2010-11-12
US20100022445A1 (en) 2010-01-28
US20150038676A1 (en) 2015-02-05
US10822376B2 (en) 2020-11-03
CN102007140A (zh) 2011-04-06

Similar Documents

Publication Publication Date Title
DK2279200T3 (en) Biological active peptides
AU2019202888B2 (en) Biologically active peptides
AU2012205202B2 (en) Biologically Active Peptides
HK1233275B (en) Biologically active peptides
HK1233275A1 (en) Biologically active peptides
HK1233275A (en) Biologically active peptides
HK1154255B (en) Biologically active peptides